Boston Scientific Corporation $BSX Shares Sold by Anchor Capital Advisors LLC

Anchor Capital Advisors LLC decreased its holdings in Boston Scientific Corporation (NYSE:BSX) by 3.1% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 481,206 shares of the medical equipment provider’s stock after selling 15,155 shares during the quarter. Boston Scientific accounts for about 1.5% of Anchor Capital Advisors LLC’s investment portfolio, making the stock its 14th largest position. Anchor Capital Advisors LLC’s holdings in Boston Scientific were worth $51,686,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. 1248 Management LLC acquired a new position in Boston Scientific in the first quarter worth approximately $26,000. Y.D. More Investments Ltd purchased a new position in Boston Scientific during the 1st quarter worth approximately $27,000. Sound Income Strategies LLC grew its position in Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 120 shares in the last quarter. Princeton Global Asset Management LLC purchased a new position in Boston Scientific during the 2nd quarter worth approximately $32,000. Finally, Oliver Lagore Vanvalin Investment Group purchased a new position in Boston Scientific during the 2nd quarter worth approximately $37,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In related news, Director Ellen M. Zane sold 2,901 shares of Boston Scientific stock in a transaction on Tuesday, October 28th. The shares were sold at an average price of $102.24, for a total value of $296,598.24. Following the completion of the sale, the director owned 24,134 shares of the company’s stock, valued at approximately $2,467,460.16. The trade was a 10.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at approximately $17,739,678.74. The trade was a 21.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 162,891 shares of company stock valued at $16,475,387. 0.50% of the stock is owned by company insiders.

Boston Scientific Stock Up 0.1%

BSX stock opened at $98.91 on Thursday. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 1 year low of $85.03 and a 1 year high of $109.50. The company has a fifty day simple moving average of $100.34 and a 200 day simple moving average of $102.43. The firm has a market cap of $146.56 billion, a PE ratio of 52.89, a PEG ratio of 2.02 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The business had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. During the same quarter in the previous year, the business earned $0.63 EPS. Boston Scientific’s quarterly revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

BSX has been the topic of several research analyst reports. Barclays lifted their price objective on shares of Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a research report on Thursday, October 2nd. Raymond James Financial lifted their price objective on shares of Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 24th. Wells Fargo & Company lifted their price objective on shares of Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Truist Financial lifted their price objective on shares of Boston Scientific from $129.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Finally, Jefferies Financial Group reiterated a “hold” rating on shares of Boston Scientific in a research report on Monday, July 21st. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $123.77.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.